Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 12:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 127 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Rhinitis, Seasonal, Allergic Clear all
Completed Phase 3 Interventional

A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)

NCT01673659
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Mometasone furoate, Nasonex Nasal Spray, Placebo nasal spray
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Jun 11, 2026, 12:45 AM EDT
Completed Phase 1 Interventional

A Study To Explore The Effect On Inflammatory Markers After Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis And The Effect Of A Single Dose Of Ibuprofen Or Fluticasone Propionate On The Allergen Response.

NCT01064726
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Ibuprofen, Fluticasone propionate, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
19 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 1, 2010 · Synced Jun 11, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients

NCT00578929
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Olopatadine Hydrochloride Nasal Spray 0.6%, Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
6 Years to 11 Years
Enrollment
2,388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Kenilworth, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Jun 11, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months

NCT00628108
View directory record Official record
Conditions
Allergic Rhinitis, Chronic Urticaria
Interventions
Levocetirizine 1.25 mg, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
6 Months to 11 Months
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Jun 11, 2026, 12:45 AM EDT
Completed Phase 4 Interventional Results available

Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis

NCT00789555
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Olopatadine hydrochloride 0.6% nasal spray (PATANASE), Olopatadine nasal spray vehicle, pH 3.7, Olopatadine nasal spray vehicle, pH 7.0
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
12 Years and older
Enrollment
1,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Jun 11, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00740792
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
azelastine HCl/fluticasone propionate, azelastine Hcl, fluticasone propionate, placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
39
States / cities
Scottsdale, Arizona • Encinitas, California • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Jun 11, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)

NCT02870205
View directory record Official record
Conditions
Seasonal Allergic Rhinitis (SAR)
Interventions
GSP 301 NS, GOM-NS, GMM-2 NS, GSP 301 placebo NS
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
12 Years and older
Enrollment
1,176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
43
States / cities
Mission Viejo, California • Orange, California • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Jun 11, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available

Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)

NCT01753739
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Bepotastine besilate, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
12 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Jun 11, 2026, 12:45 AM EDT
Completed No phase listed Observational

Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC)

NCT00985296
View directory record Official record
Conditions
Allergic Rhinoconjunctivitis
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced Jun 11, 2026, 12:45 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus or Placebo

NCT00385463
View directory record Official record
Conditions
Asthma, Seasonal Allergic Rhinitis
Interventions
Adding Advair Diskus 100/50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID
Drug
Lead sponsor
Creighton University
Other
Eligibility
15 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Jun 11, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)

NCT01024608
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Hay Fever
Interventions
Beclomethasone dipropionate, Placebo Nasal Aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Jun 11, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00651118
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo, azelastine Hcl, azelastineHcl / fluticasone propionate, fluticasone propionate
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
832 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
43
States / cities
Scottsdale, Arizona • Encinitas, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Jun 11, 2026, 12:45 AM EDT
Completed Phase 3 Interventional

Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)

NCT00163488
View directory record Official record
Conditions
Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions
Ciclesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Jun 11, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis

NCT02230696
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray, Placebo nasal spray
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 65 Years
Enrollment
951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
30
States / cities
Stockbridge, Georgia • Louisville, Kentucky • Baltimore, Maryland + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Jun 11, 2026, 12:45 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Study of AHIST in Seasonal Allergic Rhinitis Patients

NCT01008397
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
AHIST NDC#58407-012-01
Drug
Lead sponsor
Magna Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Jun 11, 2026, 12:45 AM EDT
Completed Phase 2 Interventional

The Effect of Nasal Carbon Dioxide (CO2) Used As-Needed in the Symptomatic Treatment of Seasonal Allergic Rhinitis

NCT00917020
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Nasal CO2, Inactive Placebo Gas
Drug
Lead sponsor
Capnia, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 14, 2012 · Synced Jun 11, 2026, 12:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults

NCT03814720
View directory record Official record
Conditions
Influenza Infection
Interventions
VRC-FLUNPF099-00-VP (H1ssF_3928)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Jun 11, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)

NCT01915823
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
azelastine hydrochloride and fluticasone propionate, Dymista vehicle
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
4 Years to 11 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
31
States / cities
Birmingham, Alabama • Little Rock, Alaska • Atlanta, Georgia + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Jun 11, 2026, 12:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Audio Data Collection for Identification and Classification of Coughing

NCT04326309
View directory record Official record
Conditions
COVID-19, Coronavirus Infections, Hay Fever, Asthma, Chronic Obstructive Pulmonary Disease, Influenza, Common Cold, Respiratory Tract Infections, Healthy
Interventions
Not listed
Lead sponsor
HealthMode Inc.
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Jun 11, 2026, 12:45 AM EDT
Not listed Phase 3 Interventional

Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™

NCT02249663
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Azelastine hydrochloride and Fluticasone propionate, Dymista™, Placebo
Drug · Other
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years and older
Enrollment
1,535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Jun 11, 2026, 12:45 AM EDT
Not listed Phase 2 Interventional

StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study

NCT02082054
View directory record Official record
Conditions
Rhinitis, Seasonal, Allergic
Interventions
PSE 120 mg, CM 8 mg, Atr 0.36 mg, PSE 120 mg, CM 8 mg, Atr 0.24 mg, PSE 120 mg, CM 8 mg, Atr 0.12 mg, PSE 120 mg, CM 8 mg, Atropine 0.24 mg
Drug
Lead sponsor
Magna Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 60 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Stockbridge, Georgia • Louisville, Kentucky • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Jun 11, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge

NCT00562120
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Placebo, Allegra, Allegra-D, PF-03654746
Drug
Lead sponsor
Pfizer
Industry
Eligibility
19 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Jun 11, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR

NCT00854360
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Hayfever
Interventions
Beclomethasone dipropionate HFA Nasal Aerosol, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
26
States / cities
Mission Viejo, California • San Diego, California • Colorado Springs, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Jun 11, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies

NCT01307319
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, SAR
Interventions
BDP HFA, Placebo nasal aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
45
States / cities
Oxford, Alabama • Bell, California • Costa Mesa, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2015 · Synced Jun 11, 2026, 12:45 AM EDT